| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
YH-306 targets the FAK (focal adhesion kinase) signaling pathway. It suppresses the activation of FAK, c-Src, paxillin, and PI3K, Rac1 and the expression of MMP2 and MMP9. YH-306 also inhibits actin-related protein (Arp2/3) complex-mediated actin polymerization. These targets are involved in cell migration, invasion, and metastasis.
|
|---|---|
| ln Vitro |
YH-306 suppresses colorectal tumor growth and metastasis via the FAK pathway. It significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell apoptosis. In a reporter assay using HaCaT cells, YH-306 reduces TGF-β-induced transcriptional activity by 72.4% at a concentration of 1 µM.
|
| ln Vivo |
Specific in vivo activity data for YH-306 are limited in the available literature. As an antitumor agent that suppresses colorectal tumor growth and metastasis via the FAK pathway, it is expected to exhibit efficacy in preclinical models of colorectal cancer. Further studies are needed to characterize its pharmacokinetic and pharmacodynamic profiles in animal models.
|
| Enzyme Assay |
The in vitro assay for YH-306 typically involves measuring its effects on FAK signaling and cell migration using standard biochemical and cellular techniques. The compound is tested at various concentrations, and its effects on FAK phosphorylation, cell migration, and invasion are assessed. The IC50 value is determined from the dose-response curve.
|
| Cell Assay |
The in vitro cellular assay for YH-306 typically involves culturing colorectal cancer cell lines in appropriate growth media. Cells are treated with varying concentrations of the compound, and cell migration and invasion are assessed using wound healing or Transwell assays. Cell proliferation and apoptosis are measured using MTT or flow cytometry. The compound's effects on FAK and downstream signaling are assessed using Western blotting.
|
| Animal Protocol |
In vivo animal studies for YH-306 would typically involve the use of mouse xenograft models bearing human colorectal tumors. Tumor-bearing mice would be administered the compound via appropriate routes (e.g., oral gavage or intraperitoneal injection) at various dose levels. Tumor growth and metastasis would be monitored over several weeks, and endpoints would include tumor volume measurements, body weight changes, and histopathological analysis of tumor tissues.
|
| ADME/Pharmacokinetics |
YH-306 has a molecular weight of 306.36 g/mol and a molecular formula of C19H18N2O2. It is soluble in DMSO (20 mg/mL with ultrasonic and pH adjustment to 1 with HCl). The compound should be stored at 4°C and protected from light. The purity is typically ≥99%. Further detailed PK parameters are available from the manufacturer's data sheets.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for YH-306 are not available in the public domain. The compound is intended for research use only and should be handled with appropriate laboratory safety precautions. Standard safety assessments would be required before any clinical application. Researchers should consult the safety data sheet for detailed handling and disposal information.
|
| References | |
| Additional Infomation |
YH-306 is an antitumor agent that suppresses colorectal tumor growth and metastasis via the FAK pathway. It is also known by its CAS number 1373764-75-0 and the synonyms YH 306 and YH306. The compound's ability to modulate immune responses makes it a valuable candidate for cancer immunotherapy. It has not yet entered clinical trials and is strictly for preclinical research purposes.
|
| Molecular Formula |
C19H18N2O2
|
|---|---|
| Molecular Weight |
306.36
|
| Exact Mass |
306.136
|
| CAS # |
1373764-75-0
|
| PubChem CID |
60162063
|
| Appearance |
Light yellow to light brown solid powder
|
| LogP |
2.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
433
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C=C2C(=CC=1)C1CCN(C(CC3=CC=C(C=C3)O)=O)CC=1N2
|
| InChi Key |
WFTJZQLEQGPZBC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18N2O2/c22-14-7-5-13(6-8-14)11-19(23)21-10-9-16-15-3-1-2-4-17(15)20-18(16)12-21/h1-8,20,22H,9-12H2
|
| Chemical Name |
2-(4-hydroxyphenyl)-1-(1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl)ethanone
|
| Synonyms |
YH306; YH 306; YH-306
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~65.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2641 mL | 16.3207 mL | 32.6413 mL | |
| 5 mM | 0.6528 mL | 3.2641 mL | 6.5283 mL | |
| 10 mM | 0.3264 mL | 1.6321 mL | 3.2641 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
